VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans | Zendy

Timothy J. Break | Zendy; Jigar V. Desai | Zendy; Mukil Natarajan | Zendy; Elise M. N. Ferré | Zendy; Christina Henderson | Zendy; Adrian M. Zelazny | Zendy; Ulrich Siebenlist | Zendy; William J. Hoekstra | Zendy; Robert J. Schotzinger | Zendy; Edward P. Garvey | Zendy; Michail S. Lionakis | Zendy

Open Access

VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans

Author(s) -

Timothy J. Break,

Jigar V. Desai,

Mukil Natarajan,

Elise M. N. Ferré,

Christina Henderson,

Adrian M. Zelazny,

Ulrich Siebenlist,

William J. Hoekstra,

Robert J. Schotzinger,

Edward P. Garvey,

Michail S. Lionakis

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx352

Subject(s) - fluconazole , candida albicans , microbiology and biotechnology , medicine , biology , antifungal

Candida albicans, the most common human fungal pathogen, causes chronic mucosal infections in patients with inborn errors of IL-17 immunity that rely heavily on chronic, often lifelong, azole antifungal agents for treatment. However, a rise in azole resistance has predicated a need for developing new antifungal drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research